CN114599390A - 抗体-白介素融合蛋白以及使用方法 - Google Patents

抗体-白介素融合蛋白以及使用方法 Download PDF

Info

Publication number
CN114599390A
CN114599390A CN202080055588.4A CN202080055588A CN114599390A CN 114599390 A CN114599390 A CN 114599390A CN 202080055588 A CN202080055588 A CN 202080055588A CN 114599390 A CN114599390 A CN 114599390A
Authority
CN
China
Prior art keywords
antibody
protein
antigen
disease
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055588.4A
Other languages
English (en)
Chinese (zh)
Inventor
杨岚
余国良
施前
Z·费
B·马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Guanke Meibo Biotechnology Co ltd
Original Assignee
Zhejiang Guanke Meibo Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Guanke Meibo Biotechnology Co ltd filed Critical Zhejiang Guanke Meibo Biotechnology Co ltd
Publication of CN114599390A publication Critical patent/CN114599390A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080055588.4A 2019-06-10 2020-06-10 抗体-白介素融合蛋白以及使用方法 Pending CN114599390A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/090494 2019-06-10
CN2019090494 2019-06-10
PCT/CN2020/095354 WO2020249003A1 (en) 2019-06-10 2020-06-10 Antibody-interleukin fusion protein and methods of use

Publications (1)

Publication Number Publication Date
CN114599390A true CN114599390A (zh) 2022-06-07

Family

ID=73781610

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055588.4A Pending CN114599390A (zh) 2019-06-10 2020-06-10 抗体-白介素融合蛋白以及使用方法

Country Status (6)

Country Link
US (1) US20220306713A1 (https=)
EP (1) EP3980067A4 (https=)
JP (1) JP2022537515A (https=)
CN (1) CN114599390A (https=)
CA (1) CA3143218A1 (https=)
WO (1) WO2020249003A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063547A (zh) * 2022-07-08 2023-05-05 盛禾(中国)生物制药有限公司 一种二聚体融合蛋白及其应用
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2025077212A1 (zh) * 2023-10-08 2025-04-17 广东菲鹏制药股份有限公司 抗pd1-il10融合蛋白及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126965A4 (en) * 2020-05-14 2024-10-02 Elixiron Immunotherapeutics (Hong Kong) Limited ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS
IL305758A (en) * 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
CN118434759A (zh) * 2021-10-10 2024-08-02 安立玺荣生医(香港)有限公司 用抗-pd-l1/il-10融合蛋白治疗疾病的方法
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040105A2 (en) * 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3068425B1 (en) * 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
US10435470B2 (en) * 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
US11001631B2 (en) * 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
CA3079844A1 (en) * 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040105A2 (en) * 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PELLERIN，L. 等: "APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR™) to Induce Antigen-Specific T Regulatory Type 1 Cells" *
WANG，Y. 等: "Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression" *
ZHANG，H 等: "Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063547A (zh) * 2022-07-08 2023-05-05 盛禾(中国)生物制药有限公司 一种二聚体融合蛋白及其应用
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2025077212A1 (zh) * 2023-10-08 2025-04-17 广东菲鹏制药股份有限公司 抗pd1-il10融合蛋白及其应用

Also Published As

Publication number Publication date
CA3143218A1 (en) 2020-12-17
JP2022537515A (ja) 2022-08-26
EP3980067A4 (en) 2023-08-02
EP3980067A1 (en) 2022-04-13
US20220306713A1 (en) 2022-09-29
WO2020249003A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
CN114599390A (zh) 抗体-白介素融合蛋白以及使用方法
CN110050000B (zh) 含有TGF-β受体的融合蛋白及其医药用途
CN113227146B (zh) 密蛋白18.2结合部分和其用途
US12077595B2 (en) Single domain antibodies that bind to CD137
CN107151269B (zh) 一种pdl-1抗体、其药物组合物及其用途
TWI840433B (zh) 新穎合理設計的蛋白質組合物
ES2996834T3 (en) Binding molecules with modified j-chain
AU2010303142B2 (en) Bispecific death receptor agonistic antibodies
EP3904381A1 (en) Antibody fusion protein, preparation method therefor and application thereof
CN117024592B (zh) 抗b7h3抗体及其用途
EP4155318A1 (en) Bispecific antibody and use thereof
AU2019236822B2 (en) GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
EP4389770A1 (en) Bispecific antibody and use thereof
CA3160436A1 (en) Bispecific antibodies with alternatively matched interchain cysteines and uses thereof
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
CN117355540A (zh) 抗cd137抗体和使用方法
US20250333507A1 (en) Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereof
EP4417622A1 (en) Anti-cd26 antibody and use thereof
JP7510209B2 (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
CN121079324A (zh) 抗cntn4抗体及其用途
US20240026004A1 (en) ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF
CN116891530A (zh) 双特异性抗体及其应用
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
WO2023133842A1 (zh) 一种靶向IL-18Rβ的抗体及其应用
WO2021244553A1 (zh) 一种抗pd-l1和egfr的四价双特异性抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220607

WD01 Invention patent application deemed withdrawn after publication